Document is current

Article History

Received: 9 January 2025

Accepted: 28 April 2025

First Online: 10 May 2025

Declarations

:

: The study was approved by the Institutional Review Board at Inova Fairfax hospital (IRB-2024-189) and adhered to the principles outlined in the Declaration of Helsinki. Participation in this study was entirely voluntary, and no financial or other incentives were provided. The invitation email for the survey clearly stated at the beginning that participation was voluntary and that only those who agreed to participate should proceed to complete the questionnaire. In accordance with national regulations and given the nature of the anonymous, minimal-risk survey, the IRB at Inova Fairfax hospital (IRB-2024-189) waived the requirement for written informed consent.

: Not applicable.

: SDN is a consultant and is on the speaker’s bureau for both Boehringer-Ingelheim and United Therapeutics. He has also received research funding from both Companies. He is also on the steering committee for IPF studies by Tvardi and Avalyn Pharma. CSK is a speaker for and has participated in advisory boards for United Therapeutics as well as Merck and Jannsen. CT has participated in advisory boards for Janssen. VK is a speaker for and has participated in advisory boards for Jannsen. OAS is on the speaker bureau for United Therapeutics, She is on the steering committee for PH studies for Gossamer and Insmed, and has also consulted for Merck, Janssen and Bayer. None of the other investigators have any conflicts of interest with regards to this study.